



2024 WuXi AppTec Investor Day
Research Enabling Platforms
Enhance CRDMO Model

Steve Yang, Ph.D.
Co-CEO

Forward-Looking Statements

This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings or production capacity, our ability to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor a undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. **ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES.** All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this presentation to reflect future events or circumstances, except as required under applicable law.

Non-IFRS Financial Measures

We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses and amortization of acquired intangible assets from merger and acquisition, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRS.

We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

Intellectual Property

All intellectual property rights and other rights pertaining to the information and materials presented in the presentation are owned by WuXi AppTec. Audio recording, video recording or disclosure of such materials by any means without the prior consent of WuXi AppTec is prohibited.


Disclaimer

This presentation is for information purposes only and does not constitute a recommendation regarding any securities of the Company. This presentation does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For relevant information, please refer to the Company’s disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited and the Company’s website.

WuXi Chemistry, Biology, and Testing Collaborate at Research Stage to Enhance CRDMO Business Model


Generate the Flow

by enabling discovery and research




Understand the Trends

by following science and customers



Achieve Synergy

through PCC & IND



Enable Innovation at Research Stage

WuXi Chemistry



Design



Analyze



Deliver PCC



Enable IND



Discover Targets

Develop and Run Assays

Demonstrate Efficacy

Prepare for FIH Study

WuXi Biology

WuXi Testing



Attract New Customers to WuXi AppTec CRDMO Platform

~69%



of WuXi AppTec new customers are contributed by Discovery + Preclinical in 2023



of Discovery + Preclinical 2023 new biotech customers* have fund raising events after 2019


~28%

Notes:

- 1. Including Discovery and Preclinical customers. *The customers with fund raising data are from outside of China.
- 2. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.



Generate the Flow of Compounds and Projects Through Chemistry

- During 2023H2 to 2024H1, Research Chemistry Services (RCS) delivered:
 - Over 450, 000 Compounds




Enhance Customer Engagement through Integrated Services

of Customers use both Discovery & Preclinical platforms




Revenue% of customers use both Discovery & Preclinical platforms

Reach More Long Tail Customers and Attract Them to CRDMO Platform



Understand the Trends & Build New Capability Through the Flywheel Model



Infectious Disease Market Expansion

~23%

of active customers in market*
collaborate with us since 2021




Notes:

1. According to internal analysis.
2. Including Discovery and Preclinical customers.
3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Devices.

Capability Building Flywheel for Oncology

~32%

of active customers in market* collaborate with us since 2021



End-to-end services and solutions to enable cancer drug discovery

- 1,200+ cell lines and 4,000+ disease models
- 14,000+ cancer pharmacology and clinical biomarker projects totally since 2017
- Successful IND submissions to **U.S., China and Australia**




**Integrated, on-line,
tumor model database**

Notes:

1. According to internal analysis.
2. Including Discovery and Preclinical customers.
3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.

In vivo Pharmacology Integration Across Therapeutic Areas



Notes:

1. Numbers shown on this page represent the % of active customers in market collaborate with us since 2021.
2. According to internal analysis.
3. Including Discovery and Preclinical customers.
4. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.

Small Molecule Market Expansion

~42%

of active customers in market*
collaborate with us since 2021

Research Chemistry Services (RCS) synthesized over **450,000** compounds from 2023H2 to 2024H1.

The application of **Flow Chemistry** and **Photochemistry Technologies** benefits over **90%** of our long-term partners.

Strengthen **Long Tail Strategy**, Research's long-tail customers contribute over **75%** of business volume.

In 2024H1, **380+** existing customers from the US&EU regions achieved solid growth.

Notes:


1. According to internal analysis.

2. Including Discovery and Preclinical customers.


3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents

WuXi Testing excluding clinical & Medical Device.


Early Capability Building in Emerging Technologies




Bispecific antibody




ADC




Target Protein Degradation




Stem cell



Oncolytic viruses



OBOC



Single-cell and spatial multi-omics

2014

2015

2016


2019

2020


2021

2022


2023




Cancer vaccine




Fusion protein



Oligonucleotide




Tumor Infiltrating Lymphocyte




CHIMERIC ANTIGEN RECEPTOR (CAR)
CD19⁺ T cell


CAR-T / Cell Therapy




AAV / Gene Therapy



Covalent inhibitor



Peptide DEL



RNA Editing

New Modality Market Expansion

~26%

of active customers in market*
collaborate with us since 2021



Note.:


1. According to internal analysis.

2. Including Discovery and Preclinical customers.


3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi

Testing excluding clinical & Medical Device.

Multi-Modality Expansion Supports Drug Discovery - Biology



Revenue from New Modalities & Biologics



New Modalities & Biologics Contribution to Total Revenue

Nucleic Acid Therapeutics Market Expansion

~25%

of active customers in market*
collaborate with us since 2021

Biology Revenue

+73% YOY (2023 vs 2022)

Capability and capacity

Quality and turnaround time

Experience

Solution provider

Nucleic Acid Therapeutics

Notes:

1. According to internal analysis.

2. Including Discovery and Preclinical customers.

3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.

Capability Building on Bi-Functional Degraders at WuXi Biology

Rapid Establishment and Expansion of Capability and Know-how



Capability set up during the first wave of targeted protein degrader candidates




Comprehensive platforms established in short period



Cover all discovery steps in Biology >100 targets involved



Expanded to more novel degrader types (LYTAC, AUTAC, DUBTAC, RIBOTAC, DAC, etc.)



Targeted Protein Degradator (TPD) Integrated Discovery Platform

Chemistry

- **>1000** discovery chemists, with strong experiences in the linkers, E3 ligase ligands and target protein ligands synthesis since 2016
- **>150** clients/collaborations
- **>158,000** Targeted Protein Degradators successfully delivered
- Delivered **>70** PCCs




Biology

- **>8** years of providing biology solutions to TPD
- Built **>20** assay technologies to characterize TPD molecules at different research stages
- Delivered **>300** TPD programs and **>10** moves to late development / clinical stages
- Expanded the coverage to **10+** bi-functional molecules type (including PROTAC, MGD, AUTAC, LYTAC, DUBTAC, RIBOTAC, PHICS, DAC, RIPTAC, etc.)

Targeted Protein Degradation Market Expansion

~66%

of active customers in market*
collaborate with us since 2021



Notes:

1. According to internal analysis.
2. Including Discovery and Preclinical customers.
3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.


Innovation Forefront: Enable New Biotech Companies to Discover & Develop Lifesaving Medicines from Breakthrough Sciences

Case Study: Partnership with Yale University Professor Craig Crews from Arvinas and Halda Therapeutics, WuXi AppTec was the Very First Company to Support PROTAC[®] and RIPTAC[™] Drug Discovery



ARVINAS

Arvinas - the First PROTAC[®] Company



- Arvinas' PROTAC[®] targeted protein degraders, or proteolysis-targeting chimeras, harness the body's natural protein disposal system to destroy disease-causing proteins
- Advantages: ~80% of the proteome that is currently "undruggable" may be addressable by PROTAC[®] protein degraders




8 Years' Partnership (since 2016)

- "We are the very first company to support PROTAC drug discovery"



HALDA
THERAPEUTICS

Halda Therapeutics - 'HOLD-AND-KILL' Mechanism




- RIPTAC[™] therapeutics are innovative heterobifunctional small molecules that hold together two proteins, a cancer-specific protein and a protein with essential function, resulting in abrogation of the essential cell function, and subsequently, cancer cell death
- Advantages: overcome the challenge of drug resistance and bring a new class of precision medicines to patients



5 Years' Partnership (since 2019)

- With the latest \$126 million financing, expand WuXi Chemistry "R" service
- Business partnership expand to WuXi Chemistry "D&M" for API production and WuXi Testing for preclinical studies

Harness the Power and Scale of Scientific Instruments & Deliver Success, Speed, and Efficiency to Customers




Drive Efficiency Through Automation: Bioanalytical Service

Efficiency

- Automated sample processing platform
- Digital information & lab automation system

Cutting-edge Technology

- Ultra-high sensitive peptide bioanalytical method (Picogram level)
- Comprehensive Oligo testing capabilities (Femtogram level)
- Patented cascade immunoassay extraction
qPCR detection of LNP-mRNA technology



Drive Efficiency Through Automation: DMPK

Efficiency

- TAT full process tracking and enhancement
- PK project intelligent scheduling

Cutting-edge Technology

- “Peptide / PDC MetID” solution self-developed



- European standard testing facility established
- Radiosynthesis platform




Drive Efficiency Through Automation: Toxicology

Efficiency


- Machine learning and automation technology widely applied in toxicology business

Digital Project Management

- Advanced algorithm for assignment of technicians to daily tasks
- Sophisticated technical measures to significantly improved data input and /or substitute human work




Integrated Preclinical Enabling Platform Across All Modalities





- **6 Sites:**
 - GLP: SZ · CD · QD
 - Non-GLP: SH · NJ · US
- **Automatic Full Process:**
 - TAT tracking
 - Study management
 - Bio-analytical analysis
- **One-stop solution:**
 - From “D” to “T”
 - From “R” to “T”
- **Global filling:**
 - NMPA
 - FDA
 - OECD
 - PMDA


Drive Preclinical Conversion Through CRDMO Business Model




Seamless Collaboration: One-Stop Integrated IND Solution



Strong Momentum For Preclinical IND Project Flow



Well Established Peptide Preclinical Testing Capabilities Since 2015



Trusted Preclinical Testing Platform Enables Global Licensing

80%+

**WuXi Testing
Enabled customers global licensing in 2024 H1**


67%

**Enabled out licensing of ADC molecules
in 2024 H1**

52%

**Enabled out licensing of small molecules
in 2024 H1**

Maintain the Highest Global Regulatory Standards



Meeting Global Quality Standard

Case Study: WuXi AppTec “Race Car” Enables Innovation



Sam Clark, CEO, Terran Bioscience

“ We would not have been able to achieve the level of **speed** with which we developed new inventions.

We first looked in the U.S. There weren't any that could give us **200 chemists** at a moment's notice to work on a new project.

We are highly impressed with the **capabilities of the WuXi “race car”**.

— STAT News, June 6, 2024 ”

RCS (R)

- High Chemical Complexity
- Patent Submission Date Booked
- Resource Integration, Cross-Site Collaboration
- Same-Day Completion, Handover to DMPK

LTD (T)

- Seamless Transition Testing
- Client Collaboration with Multiple Departments Including LTD, e.g. DMPK Testing

STA (D)

- Key Client Urgent Project
- Supply of Intermediate Raw Materials
- Entering Critical Phase

200+ FTE during peak periods

6 weeks delivered **240+** Compounds/

Largest Order from **New Clients**

BD support



Speed

Flexibility

Efficiency

Execution

Achieve Customer Satisfaction and Maintain High Retention Rates

Empower Customers

Enable Innovation

Build Trust



70%+ revenue contributor

97%

2022

98%

2023

98%

2024H1





Notes:

1. TOP 300 WuXi Discovery + Preclinical customers.

2. Retention: the ratio that TOP 300 customers in revenue of previous year which still work with us this year.



Continue Increase of the Number of Active Customers Across Globe



Notes:

- 1. Numbers shown on this page represent the YoY% of active customers.
- 2. Including Discovery and Preclinical customers.
- 3. Discovery represents WuXi Biology and RCS (Research Chemistry Services); Preclinical represents WuXi Testing excluding clinical & Medical Device.

Integrated Research Platform Enabling CRDMO Business Model One-Stop Solution at WuXi AppTec



Med Chem,
Synthesis and
Manufacturing

Hit Finding
Hit to Lead
Lead Optimization

ADME/Tox
DMPK
IND-Enabling and
Packaging

WuXi AppTec